


## Hypoxanthine-<sup>13</sup>C<sub>5</sub>,<sup>15</sup>N<sub>4</sub>

<b>Cat. No.:</b>	HY-N0091S
<b>CAS No.:</b>	1987883-25-9
<b>Molecular Formula:</b>	<sup>13</sup> C <sub>5</sub> H <sub>4</sub> <sup>15</sup> N <sub>4</sub> O
<b>Molecular Weight:</b>	145.05
<b>Target:</b>	Endogenous Metabolite; Isotope-Labeled Compounds
<b>Pathway:</b>	Metabolic Enzyme/Protease; Others
<b>Storage:</b>	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 10 mg/mL (68.94 mM; Need ultrasonic and warming)

Concentration	Mass			
	1 mg	5 mg	10 mg	
1 mM	6.8942 mL	34.4709 mL	68.9417 mL	
5 mM	1.3788 mL	6.8942 mL	13.7883 mL	
10 mM	0.6894 mL	3.4471 mL	6.8942 mL	

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Hypoxanthine-<sup>13</sup>C<sub>5</sub>,<sup>15</sup>N<sub>4</sub> is a <sup>15</sup>N-labeled and <sup>13</sup>C-labeled Dansyl chloride.

#### In Vitro

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs<sup>[75]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-245.

[2]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-245.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA